Picard Medical, Inc. (PMI) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Picard Medical, Inc. (PMI) operates as a holding company for SynCardia Systems, which designs and manufactures the SynCardia Total Artificial Heart (TAH), an FDA-approved device for patients with end-stage heart failure. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of May 11, 2026, there were approximately 92.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $1.15 million | $0.62 million |
| Gross Profit | $0.28 million | ($0.36 million) loss |
| Operating Loss | ($4.51 million) | ($3.25 million) |
| Net Loss | ($7.62 million) | ($5.56 million) |
| Cash and Cash Equivalents (End of Period) | $0.12 million | $0.69 million |
| Total Assets | $11.22 million | $22.55 million |
| Total Liabilities | $12.67 million | $18.76 million |
| Stockholders' Equity (Deficit) | ($1.45 million) | $3.79 million |
Liquidity Note: Cash and cash equivalents dropped from $7.45 million (including restricted cash) at year-end 2025 to $0.12 million at March 31, 2026. The company reported a negative working capital position.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 85% year-over-year, driven by a 54% increase in product sales ($0.94M vs $0.61M) and a significant surge in rental revenue ($0.21M vs $0.01M). All Q1 2026 revenue was generated in the United States.
- Profitability: The company moved from a gross loss in Q1 2025 to a gross profit in Q1 2026. However, the Net Loss widened by 37% to $7.62 million.
- Debt Settlement Impact: The increase in net loss was primarily driven by a $6.1 million loss on settlement of debt and a $3.0 million gain from changes in the fair value of the Senior Secured Note and warrant liabilities. In Q1 2025, losses were driven by derivative losses and interest expense.
- Operating Expenses: Operating expenses increased 66% to $4.79 million. Research and Development (R&D) expenses rose 135% to $1.90 million due to new product research, while SG&A increased 39% to $2.89 million, largely due to professional and legal fees.
- Balance Sheet: Total assets decreased by 50% primarily due to the repayment of the Senior Secured Note and the conversion of debt to equity. Stockholders' equity turned negative, moving from a surplus of $3.79 million to a deficit of $1.45 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of the report due to recurring operating losses and negative cash flows. Additional financing is required to fund operations.
- NYSE Compliance: On May 8, 2026, PMI received a notice of noncompliance from NYSE American regarding the Stockholders' Equity Rule (due to negative equity and recent net losses). The company must submit a compliance plan by June 7, 2026, to regain compliance by November 8, 2027. Failure to comply could result in delisting.
- Subsequent Events (Post-March 31, 2026):
- May 2026 Offering: Completed a public offering raising gross proceeds of $5.0 million (net $3.06 million) to settle debt and fund operations.
- Debt Settlement: Settled additional Senior Secured Note principal via cash and equity issuance in April and May 2026.
- Warrant Exchange: Entered an agreement to exchange existing warrants for new warrants with a lower exercise price ($0.35).
- Legal Proceedings: A putative securities class action lawsuit (Louie v. Picard Medical, Inc.) was filed in February 2026 alleging false statements regarding the IPO. The company intends to defend vigorously but cannot estimate potential losses.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and lack of formal review processes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.06 million net proceeds from the May 2026 offering against the company's burn rate and remaining debt obligations.
- NYSE Compliance Plan: Monitor the submission and acceptance of the compliance plan by June 7, 2026, to assess delisting risk.
- Debt Structure: Review the terms of the remaining Senior Secured Note and the new warrants issued in the May 2026 exchange, specifically regarding dilution and future cash settlement requirements.
- Customer Concentration: Note that Customer A accounted for 68% of Q1 2026 revenue; assess the risk of losing this single major customer.
- Going Concern Status: Evaluate the likelihood of securing further equity or debt financing given the current market conditions and the company's negative equity position.